Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023

Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, new and updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 to June 6 in Chicago, IL.

Results from the pivotal phase 2b HERIZON-BTC-01 study of zanidatamab in previously treated HER2-amplified biliary tract cancer (abstract #4008) will be presented by Dr. Shubham Pant in an oral presentation on Friday, June 2, during the Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Session from 2:45-5:45 pm Central Daylight Time (CDT).

Updated clinical data from a phase 1b/2 study evaluating zanidatamab in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer (abstract #1044) will be presented in the Breast Cancer-Metastatic poster session on Sunday, June 4 from 8:00-11:00 am CDT.

The presentations will be available to conference registrants on the conference website as well as to the general public at www.zymeworks.com/publications at the time of presentation at the conference.